Bio-Link Australia Pty. Ltd.

Please find below a list of selected recent news and press releases from Bio-Link’s clients.

7th May 2017 – Oncology Venture – New APO010 multiple myeloma trial initiation

Oncology Venture, a precision oncology biopharmaceutical company and Bio-Link client, has recently announced important milestones in the development of its phase I/II immuno-oncology drug candidate APO010, granting of a key US patent for phase II ready drug candidate irofulven, and validation of its platform precision medicine technology, Drug Response Predictor™ (DRP™):

The first multiple myeloma patient was treated with APO010 in a phase 1/2 trial, by utilising the proprietary APO010 DRPTM companion diagnostic to select highly likely responders. Read more
Oncology Venture’s successful patent strategy is evident through a recently granted US patent covering the DRPTM and Irofulven. Irofulven is a potent anti-cancer drug candidate that will be tested in a focused phase 2 trial in likely patient responders with castration-resistant prostate cancer. Read more
The predictive power of the DRPTM was the topic of Oncology Venture’s recent ASCO poster presentation, demonstrating that it successfully predicts response to epirubicin, one of the most used breast cancer treatments. The DRPTM was significantly associated with Progression Free Survival (PFS) in a cohort of 135 metastatic breast cancer patients. Read more

28th March 2017 – Oncology Venture – APO010 approved for testing in phase II multiple myeloma trial

Oncology Venture’s immuno-oncology drug APO010, a first-in-class FAS-ligand, will be tested in a subset of Multiple Myeloma patients identified as likely responders by the Drug Response Predictor (DRPTM) precision medicine technology. Read Full Story Here

14th February 2017 – Neural Diagnostics Awarded A$2.2M in CRC-P Grant

Neural Diagnostics Pty Ltd, a Melbourne-based medtech developer, have been awarded $2.2M in a 2nd round CRC-P grant to develop their EVestG™ technology for medical applications in the field of head trauma. The project is a collaboration with GE Healthcare and Monash University that is expected to be completed in 3 years at a total expenditure of $8.1M.

EVestG™ (ElectroVestibuloGraphy) is a novel technology and medical device that enables a simple, non-invasive test for the objective and accurate classification of a range of neurological diseases, including Alzheimer’s, Parkinson’s, autism spectrum disorder, bipolar disorder, depression, Ménière’s disease, schizophrenia and concussion. Potential applications for EVestG™ range from streamlining development of CNS drugs to clinical diagnostics to workplace safety and more.

CRC-Ps are a stream of the Australian CRC Programme in which a small group of collaborators work on a single, short term, industry-identified and industry-led collaborative research project to develop a product, service or process that will solve problems for business and deliver tangible outcomes.

Neural Diagnostics have engaged Bio-Link to facilitate business development and strategic partnerships for EVestG™.

29th August 2016 – Oncology Venture – First metastatic breast cancer patient with LiPlaCis™ confirmed partial response

Oncology Venture has announced that the first patient with metastatic breast cancer included in its LiPlaCis™ extension – proof of concept trial has obtained a confirmed Partial Remission (ie >30% tumour reduction) (press release link). The patient is the first of 12-15 patients whose tumour tissue has been pre-screened as a highly likely responder by Oncology Venture’s Drug Response Predictor (DRP™). Bio-Link is seeking partners to co-develop or secure rights to LiPlaCis™. Click here for full press release.

December 11th – CMRI awarded A$10mil grant from the ACRF

The Children’s Medical Research Institute has won a record-breaking A$10 million grant from the Australian Cancer Research Foundation. The A$10 million grant is one of the largest grants for medical research equipment in Australian history and will be used to establish The ACRF International Centre for the Proteome of Cancer (ProCan) at the Children’s Medical Institute in Westmead. The centre will be working to analyse tens of thousands of samples of cancer for precise protein levels in small biopsies. In phase two of the project, advanced computer analysis will compare the protein data with already available data for each cancer, providing a major step forward for cancer diagnosis and treatment. For more information, please see the press release.

8th September 2015 – Children’s Cancer Institute and Sydney Children’s Hospital Network launch new joint initiative

Children’s Cancer Institute in conjunction with Sydney Children’s Hospital Network have launched an Australian first initiative to treat high-risk child cancer patients with patient specific tailored treatments. The program Zero Childhood Cancer is focused on detailed laboratory analysis on each child’s unique cancer cells to help identify which treatment is best suited for their specific cancer. The goal of this program is to achieve a 100% survival rate in childhood cancer in the future. Please see CCI’s press release here.

30th June 2015 – Mirxx Therapeutics wins court proceedings over IP

Mirrx Therapeutics has won in proceedings in the Danish Supreme Court against Roche Innovation Center Copenhagen, formerly Santaris Pharma A/S. This win confirms Mirrx as the rightful owner of their exciting Blockmir technology. Please see Mirrx’ press release here.

7th January 2015 – Sydney Children’s Hospital Network produce exciting PKU therapeutic proof of principle data

Sydney Children’s Hospital Network have generated exciting in vivo proof of principle data, showing that their GM probiotic significantly limits phenylalanine blood levels in PahENU2 mice (a model of phenylketonuria, PKU), offering the prospect of an efficacious, orally bioavailable probiotic for PKU patients.

Older News